Calendario›REGN›Olatorepatide

Olatorepatide

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Ensayo de REGENERON PHARMACEUTICALS, INC. en Overweight or Obesity (del registro, en inglés).

Fase

Fase 2

Estado

Reclutando pacientes

Participantes

360

previstos

Centros

18

Fin del objetivo primario

ene 2028

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en jul 2026.

Qué mide

Occurrence of Treatment-Emergent Adverse Events (TEAEs) (del registro, en inglés) (hasta unas 60 semanas)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07685808), actualizada en sep 2026.